Forbes April 11, 2022
Topline
German biotech BioNTech on Monday highlighted compelling preliminary data from a clinical trial evaluating a new mRNA-based cancer therapy, an early indication the technology behind some of the most effective Covid-19 vaccines could potentially unlock new treatments for cancer as well as targeting other infectious diseases.
Key Facts
What We Don’t Know
Whether the treatment works. There is not enough data to properly evaluate how effective this new treatment combination might be, if at all. It is also possible new safety issues and side effects could emerge in larger, longer trials. Only a few of the patients in the trial—five, or around a third—were actually given the CARVac vaccine, and more data will be needed to demonstrate its role...
Today's Sponsors
Today's Sponsor